| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_086a68f295e770fe8d06bf290fcc7889 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 |
| filingDate |
2018-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ef26b95a5abc6f86b46bf008d9e91ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f195ccfa34676cf6c5db0428d2b20eba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8aca955cba79a09987ded1aa11472777
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4815473a9c48c5e9d15820d54006072b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6f3d7bc275d53465428ee553eed3c1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f01cba7d103d430ff82f1988339f202c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baaed6df2a029a1e15606ea869a119b0 |
| publicationDate |
2019-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019062250-A1 |
| titleOfInvention |
Therapeutic agent and application comprising the isolated recombinant oncolytic adenovirus and NK cells, kit, method for treating tumor and/or cancer |
| abstract |
The invention relates to a therapeutic agent comprising an isolated recombinant oncolytic adenovirus and an NK cell, an application, a kit and a method for treating a tumor and / or cancer. The therapeutic agent comprises: a first pharmaceutical composition, the first pharmaceutical composition comprising a recombinant oncolytic adenovirus in a first pharmaceutically acceptable vehicle; and a second pharmaceutical composition, the second pharmaceutical composition comprising an NK cell in a second pharmaceutically acceptable vehicle. The recombinant oncolytic adenovirus is a selective replication oncolytic adenovirus, and an exogenous siRNA coding sequence capable of inhibiting the expression of PDL1 in tumor cells is integrated into a recombinant oncolytic adenovirus genome. The oncolytic destructive effect of the recombinant oncolytic adenovirus and the anti-tumor immunostimulatory effect of a T-cell produce a synergistic effect. The use of recombinant oncolytic adenovirus and NK cell in combination can produce a synergistic effect of additional tumor destruction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110325200-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110325200-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110248671-A |
| priorityDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |